Compare Enbridge Inc (ENB) vs Hims and Hers Health Inc (HIMS) Price & Performance

ENB trades at $46.465, up 1.25% today, with a bearish technical signal but strong fundamentals including three consecutive quarterly EPS beats and a 6% dividend yield. Revenue grew to $65.19B in 2025, with net income of $7.49B, though profit margins have fluctuated. Analyst consensus is mixed with a $61.63 price target, while recent news highlights its stable cash flow and expansion into renewables.

The outlook balances a high yield and growth projects against interest rate sensitivity and debt levels near 49% of assets. Upside exists if execution on the $41B backlog drives earnings, but macroeconomic pressures and technical weakness pose near-term risks for shareholders.

Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.

The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.